Gilead Sciences, Inc. (GILD)
After hours:
| Previous Close | 62.24 |
| Open | 62.42 |
| Bid | 63.03 x 900 |
| Ask | 63.18 x 800 |
| Day's Range | 61.80 - 63.21 |
| 52 Week Range | 57.19 - 74.12 |
| Volume | |
| Avg. Volume | 10,015,433 |
| Market Cap | 79.247B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 17.65 |
| EPS (TTM) | 3.58 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | 2.92 (4.69%) |
| Ex-Dividend Date | Jun 14, 2022 |
| 1y Target Est | 69.52 |
- Zacks
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
- Business Wire
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
FOSTER CITY, Calif., May 16, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP). As previously announced, the FDA had placed a clinical hold on the use of injectable lenacapavir in borosilicate vials due to a vial compatibility issue. FDA removed the clinical
- Simply Wall St.
Did Gilead Sciences, Inc. (NASDAQ:GILD) Use Debt To Deliver Its ROE Of 23%?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
